#USA #Clark #Nevisense #Skin Cancer #Metropolitan Dermatology

Metropolitan Dermatology Introduces Nevisense® Technology

A Leap Forward in Melanoma Detection

Metropolitan Dermatology has made an exciting advancement in skin cancer diagnosis by introducing Nevisense®, a state-of-the-art non-invasive melanoma detection technology. Available at their Newton, Clark, and Vineland locations in New Jersey, this cutting-edge tool is now accessible to patients seeking accurate and efficient skin evaluations.

Nevisense® employs electrical impedance spectroscopy (EIS), a sophisticated technique that analyzes suspicious moles by examining them beneath the skin’s surface. This innovative method provides healthcare professionals with critical information that goes beyond traditional visual examinations, facilitating earlier and more precise detection of melanoma, a notably deadly form of skin cancer.

Importance of Early Detection

Dr. Alex Doctoroff, CEO and Medical Director at Metropolitan Dermatology, emphasizes the pivotal role of early diagnosis in successful melanoma treatment. "Early detection is critical when it comes to melanoma. By incorporating Nevisense® into our practice, we give our patients access to one of the most advanced diagnostic tools available today, enhancing both diagnosis accuracy and patient peace of mind," noted Dr. Doctoroff.

Key Advantages of Nevisense®

Nevisense® boasts several key advantages that improve the melanoma detection process:
1. Non-invasive and Painless Evaluation: The technology offers a comfortable experience for patients, eliminating the need for intrusive procedures.
2. Improved Diagnostic Accuracy: Nevisense® enhances the diagnostic capabilities when combined with visual examinations and dermoscopy, leading to better clinical outcomes.
3. Reduced Need for Biopsies: By minimizing unnecessary biopsies, the technology helps patients avoid unnecessary discomfort and potential scarring.
4. Support for Early Detection: Its focus on early diagnosis is crucial for the successful treatment of melanoma, making it an invaluable resource for dermatology practices.

Embracing Innovation in Dermatology

The introduction of Nevisense® underscores Metropolitan Dermatology's commitment to integrating innovative technologies into patient care. This FDA-approved tool has seen extensive use in Europe, paving the way for its launch in the United States. It exemplifies the practice's dedication to offering cutting-edge solutions in dermatology, ensuring that patients receive the best diagnostic care available.

Patients in the Newton, Clark, and Vineland areas can now experience the advantages of Nevisense® as a part of their comprehensive skin evaluations. For those interested in learning more about this technology or scheduling an appointment, they can reach out to Metropolitan Dermatology at (877) 458-9070 or visit their website at MetropolitanDerm.com.

About Metropolitan Dermatology

Operating in both New Jersey and Staten Island, New York, Metropolitan Dermatology is a leading provider in the field of medical, surgical, and cosmetic dermatology. The practice prides itself on offering a tailored approach to each patient's unique needs, supported by a team of expert specialists dedicated to the latest advancements in dermatologic care. With a total of 22 convenient locations, they continue to expand their services while upholding a high standard of patient care.

For media inquiries, please contact:
Kristine Walters
VP of Operations, Metropolitan Dermatology
732-574-1399, ext. 222
[email protected]

Conclusion

The launch of Nevisense® is not just a step forward for Metropolitan Dermatology but for all patients seeking comprehensive skin evaluations. By prioritizing early detection of melanoma through advanced technology, patients can benefit from improved health outcomes and peace of mind.